Royal Bank of Canada
PCVX icon

Royal Bank of Canada’s Vaxcyte PCVX Stock Holding History

Royal Bank of Canada’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$496K Sell
8,551
-673
-7% -$36.5K ﹤0.01% 4143
2025
Q4 		$426K Sell
9,224
-939,825
-99% -$42M ﹤0.01% 4287
2025
Q3 		$34.2M Buy
949,049
+199,657
+27% +$6.61M 0.01% 1232
2025
Q2 		$24.4M Buy
749,392
+719,921
+2,443% +$23.6M ﹤0.01% 1400
2025
Q1 		$1.11M Buy
29,471
+15,774
+115% +$1.26M ﹤0.01% 3384
2024
Q4 		$1.12M Buy
13,697
+5,207
+61% +$517K ﹤0.01% 3450
2024
Q3 		$969K Sell
8,490
-2,541
-23% -$229K ﹤0.01% 3578
2024
Q2 		$832K Buy
11,031
+7,742
+235% +$527K ﹤0.01% 3607
2024
Q1 		$224K Sell
3,289
-25,461
-89% -$1.76M ﹤0.01% 4600
2023
Q4 		$1.8M Buy
28,750
+16,804
+141% +$873K ﹤0.01% 3157
2023
Q3 		$609K Buy
11,946
+5,926
+98% +$292K ﹤0.01% 3873
2023
Q2 		$300K Buy
6,020
+1,779
+42% +$84.3K ﹤0.01% 4388
2023
Q1 		$159K Sell
4,241
-6,055
-59% -$257K ﹤0.01% 4815
2022
Q4 		$494K Buy
10,296
+9,439
+1,101% +$370K ﹤0.01% 4122
2022
Q3 		$21K Buy
857
+359
+72% +$9.1K ﹤0.01% 6118
2022
Q2 		$10K Sell
498
-2,321
-82% -$53.7K ﹤0.01% 6387
2022
Q1 		$68K Sell
2,819
-5,858
-68% -$128K ﹤0.01% 5891
2021
Q4 		$207K Buy
8,677
+3,790
+78% +$88.1K ﹤0.01% 5302
2021
Q3 		$124K Buy
4,887
+1,965
+67% +$47.6K ﹤0.01% 5559
2021
Q2 		$66K Buy
2,922
+418
+17% +$8.56K ﹤0.01% 5855
2021
Q1 		$50K Buy
2,504
+1,979
+377% +$49.8K ﹤0.01% 5884
2020
Q4 		$14K Buy
525
+305
+139% +$11.3K ﹤0.01% 6231
2020
Q3 		$11K Buy
220
+20
+10% +$796 ﹤0.01% 5897
2020
Q2 		$6K Buy
+200
New +$6.43K ﹤0.01% 6000

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada's PCVX Position: Q1 2026 in Review

Royal Bank of Canada reduced its Vaxcyte (PCVX) stake by 7.3% in Q1 2026, selling an estimated $36.5K and leaving 8,551 shares worth $496K. The position accounts for ﹤0.01% of the portfolio, ranked #4143.

Royal Bank of Canada first reported a position in PCVX in Q2 2020 and has held it in 24 quarters since. The position peaked at $34.2M in Q3 2025. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Royal Bank of Canada held 8,551 shares of Vaxcyte worth $496K as of Q1 2026.
  • Royal Bank of Canada sold 673 Vaxcyte shares in Q1 2026, an estimated $36.5K.
  • Vaxcyte made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4143 holding.
  • Royal Bank of Canada first reported a position in Vaxcyte in Q2 2020 and has held it in 24 quarters since.
  • Royal Bank of Canada's Vaxcyte position peaked at $34.2M in Q3 2025.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.